期刊文献+

某院2011~2015年鲍曼不动杆菌感染分布及耐药性变迁 被引量:7

Distribution and changes of drug resistance of Acinetobacter Baumannii infection from 2011 to 2015
下载PDF
导出
摘要 目的回顾分析某院2011~2015年分离鲍曼不动杆菌感染临床分布及耐药性变迁,为临床经验治疗鲍曼不动杆菌感染提供数据支持。方法使用Microscan Walkaway 40plus型全自动微生物鉴定及药敏分析仪对临床分离株进行鉴定及抗菌药物最低抑菌浓度检测,采用WHONET 5.6版软件对数据进行统计分析。结果 2011~2015年分别分离到鲍曼不动杆菌190株、269株、350株、336株、427株,分别检出碳青霉烯耐药鲍曼不动杆菌159株、222株、294株、281株、356株。鲍曼不动杆菌主要来源于ICU(559株,35.6%)、神经外科(276株,17.6%)、呼吸内科(271株,17.2%)等科室,主要分离自痰液(1 201株,76.4%)、伤口切口分泌物(124株,7.9%)、尿液(81株,5.2%)等标本。鲍曼不动杆菌对青霉素类、青霉素类/β内酰胺酶抑制剂复合物、头孢菌素类、碳青霉烯类、氨基糖苷类、喹诺酮类、四环素类耐药率均超过了80%。碳青霉烯耐药鲍曼不动杆菌对检测的所有抗菌药物耐药率高于总耐药率,对青霉素类、青霉素类/β内酰胺酶抑制剂复合物、头孢菌素类、碳青霉烯类、氨基糖苷类、喹诺酮类、四环素类耐药率均超过了95%。结论鲍曼不动杆菌耐药形势严峻,临床科室应根据微生物培养报告合理选择抗菌药物,同时应加强院内感染控制工作,避免碳青霉烯耐药鲍曼不动杆菌暴发流行。 Objective To investigate the clinical distribution and drug resistance of Acinetobacter Baumannii and to provide evidence of rational drug use for the treatment of Acinetobacter Baumannii infections.Methods The strains and the minimum inhibitory concentration were identified by using Microscan Walkaway 40 plus.The data were analyzed by the software of WHONET 5.6.Results From 2011 to 2015,totally 190,269,350,336 and 427strains of Acinetobacter Baumannii were isolated respectively and159,222,294,281 and 356strains of carbapenem resistant Acinetobacter Baumannii were isolated respectively.Patients who were infected by Acinetobacter Baumannii were mainly distributed in intensive care unit(559strains,which accounted for 35.6%),neurosurgery(276strains,which accounted for 17.6%),and respiratory medicine(271strains,which accounted for 17.2%).There were 1 201,124 and 81strains which were mainly isolated form sputum(76.4%),wound incision secretions(7.9%)and urine(5.2%).Drug resistance rates of Acinetobacter Baumannii to penicillins,penicillin class/β-lactamase inhibitor combinations,cephalosporins,carbapenems,aminoglycosides,quinolones and tetracyclines were all higher than 80%.Drug resistance rates of carbapenem resistant Acinetobacter Baumannii to penicillins,penicillin class/β-lactamase inhibitor combinations,cephalosporins,carbapenems,some aminoglycosides,quinolones and tetracyclines were all higher than 95%,which were also higher than the total drug resistance rates.Conclusion The condition of drug resistance of Acinetobacter Baumannii is serious.Clinical departments should choose antibiotics reasonably according to microbiological culture report and should strengthen the hospital infection control to avoid outbreak of carbapenem resistant Acinetobacter Baumannii.
出处 《检验医学与临床》 CAS 2016年第21期3016-3018,共3页 Laboratory Medicine and Clinic
关键词 鲍曼不动杆菌 碳青霉烯耐药鲍曼不动杆菌 耐药率 经验用药 Acinetobacter Baumannii carbapenem resistant Acinetobacter Baumannii drug resistance rate rational drug use
  • 相关文献

参考文献12

  • 1白娟,钟山,钱小亮,吴寅,王婧雯,闫丹,徐修礼,文爱东.某院2011~2013年鲍曼不动杆菌临床分布及耐药性分析[J].药物流行病学杂志,2015,24(2):111-113. 被引量:1
  • 2苏青,范琳,于景云.鲍曼不动杆菌的临床分布及耐药性监测[J].中国微生态学杂志,2015,27(1):80-82. 被引量:10
  • 3Janahiraman S, Aziz MN,Hoo FK,et al. Resistance pat-terns of multidrug resistant acinetobacter baumannii in anICU of a tertiary care hospital, Malaysia[J]. Pak J MedSci,2015,31(6) :1383-1388.
  • 4Lemos EV,De La Hoz FP,Einarson TR,et al. Carbapen-em resistance and mortality in patients with Acinetobacterbaumannii infection: systematic review and meta-analysis[J]. Clin Microbiol Infect,2014,20(5) :416-423.
  • 5Beceiro A, Moreno A, Fernandez N. et al. Biological costof different mechanisms of colistin resistance and theirimpact on virulence in Acinetobacter baumannii[J]. Anti-microb Agents Chemother,2014,58(1) :518-526.
  • 6胡付品,朱德妹,汪复,蒋晓飞,徐英春,张小江,张朝霞,季萍,谢轶,康梅,王传清,王爱敏,徐元宏,沈继录,孙自镛,陈中举,倪语星,孙景勇,褚云卓,田素飞,胡志东,李金,俞云松,林洁,单斌,杜艳,韩艳秋,郭素芳,魏莲花,吴玲,张泓,孔菁,胡云建,艾效曼,卓超,苏丹虹.2014年CHINET中国细菌耐药性监测[J].中国感染与化疗杂志,2015,15(5):401-410. 被引量:727
  • 7胡付品,朱德妹,汪复,蒋晓飞,孙自镛,陈中举,胡志东,李金,谢轶,康梅,徐英春,张小江,张朝霞,季萍,王传清,王爱敏,倪语星,孙景勇,俞云松,林洁,储云卓,田素飞,徐元宏,沈继录,单斌,杜艳,卓超,苏丹虹,张泓,孔菁,魏莲花,吴玲,胡云建,艾效曼.2013年中国CHINET细菌耐药性监测[J].中国感染与化疗杂志,2014,14(5):365-374. 被引量:622
  • 8Pogue JM,Mann T,Barber KE,et al. Carbapenem-resist-ant Acinetobacter baumannii: epidemiology, surveillanceand management[J]. Expert Rev Anti Infect Ther,2013,11(4):383-393.
  • 9Al-Agamy MH,Khalaf NG,Tawfick MM,et al. Molecu-lar characterization of carbapenem-insensitive Acineto-bacter baumannii in Egypt [J]. Int J Infect Dis,2014,22(5):49-54.
  • 10Pasanen T,Koskela S, Mero S, et al. Rapid molecularcharacterization of Acinetobacter baumannii clones withrep-PCR and evaluation of carbapenemase genes by newmultiplex PCR in Hospital District of Helsinki and Uusi-maa[J]. PLoS One,2014,9(1) :e85854.

二级参考文献100

  • 1Arias CA. Murray BE. Antibiotic-resistant bugs in the 21st century-a clinical super-challenge[J].N Engl J Med. 2009. 360(5): 439-443.
  • 2Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing[S]. Twentyfourth informational supplement. 2014. M100-S24 Vol 34 No. 1.
  • 3Hu F. Chen S. Xu X. et al. Emergence of carbapenem-resistant clinical Enterobacteriaceae isolates from a teaching hospital in Shanghai. China[J]. J Med Microbiol , 2012. 61 (Pr 1): 132- 136.
  • 4Brink AJ. Feldman C. Grolman DC. et al. Appropriate use of the carbapenems[J]. S Afr Med J. 2004. 94 (10 Pt 2): 857-861.
  • 5Chen S. Hu F. Zhang X. et al. Independent emergence of colistin-resistant Enterobacteriaceae clinical isolates without colistin treatrnentj]]. J Clin Microbiol , 2011. 49( 11): 4022- 4023.
  • 6van Duin D. Kaye KS. Neuner EA. et al. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes[J]. Diagn Microbiol Infect Dis. 2013. 75(2): l1S-120.
  • 7Daikos GL. Tsaousi S. Tzouvelekis LS. et al. Carbapenemaseproducing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems [J]. Antimicrob Agents Chernother , 2014.58 (4): 2322-2328.
  • 8Tascini C. Tagliaferri E. Giani T. et al. Synergistic activity of colistin plus rifampin against colistin-resistant KPCproducing Klebsiella pneumoniae [J]. Antimicrob Agents Chernother , 2013. 57 (8): 3990-3993.
  • 9Pulcini C. Bush K. Craig WA. et al. Forgotten Antibiotics: an Inventory in Europe. the United States. Canada. and Australia[J]. Clin Infect Dis. 2012. 54(2): 268-274.
  • 10Falagas ME. Giannopoulou KP. Kokolakis GN. et al. Fosfomycin , use beyond urinary tract and gastrointestinal infections [J]. Clin Infect Dis. 2008. 46(7): 1069-1077.

共引文献1283

同被引文献55

引证文献7

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部